The clinical features of severe community-acquired pneumonia presenting as septic shock

Journal of Critical Care

Volumn 15, Issue 3, 2000, Pages 85-90

  Marik, Paul E ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Norasept II Study Investigators   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ACINETOBACTER; ADULT; ALCOHOL ABUSE; ARTICLE; BACTERIUM ISOLATION; CLINICAL FEATURE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SCORING SYSTEM; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034493896     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcrc.2000.16460     Document Type: Article

References (47)

1. National Center for Health Statistics. Mortality Patterns-United States, 1990
2. Annual summary of births, marriages, divorce, and deaths. United States, 1993
3. Community-acquired pneumonia
4. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
5. Severe cummunity-acquired pneumonia: Etiology, epidemiology and prognosis factors
6. Prognosis and out-comes of patients with community acquired pneumonia: A mela-analysis
7. Severe community-acquired pneumonia in ICUs: Prospective validation of a prognostic score
8. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit
9. Severe community-acquired pneumococcal pneumonia. The French Study Group of Community-Acquired Pneumonia in ICU
10. Severe community-pneumonia: Ecology, prognosis, and treatment
11. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia
12. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis assessment of severity and initial antimicrobial therapy
13. Community-acquired pneumonia in adults: Guidelines for management
14. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock
15. Mice deficient for the 55-kd tumor necrosis factor receptor are resistant endotoxic shock, yet succumb to L. monocytogenes infection
16. The toxic and hematologic effects of interleukin-1 alpha administered in a phase trial of patients with advanced hematologic malignancies
17. Tumor necrosis factor infusions in humans prime neutrophils for hypochlorous acid production
18. Prognostic factors of pneumonia requiring admission to the intensive care unit
19. Community acquired pneumonia in the intensive care unit
20. Severe community-acquired pneumonia in she elderly: Epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia
21. Impact of management guidelines on the outcome of severe community acquired pneumonia
22. Etiology and diagnosis of pneumonia requiring IUD admission
23. Severe community-acquired pneumonia epidemiology and prognostic factors
24. Severe community-acquired pneumonia: What do we need to know to effectively manage patients?
25. Severe community-acquired pneumonia
26. Community-acquired acinetobacter pneumonia
27. High alcohol intake as a risk and prognostic factor for community acquired pneumonia
28. APACHE 11: A severity of disease classification system
29. Plasma proinflammatory cytokine concentrations. Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit
30. Bedside prediction of mortality from bacteremic sepsis: A dynamic analysis of ICU patients
31. Evaluation of predictive ability of APACHE II system and hospital outcome in Canadian intensive care unit patients
32. Evaluation of Acute Physiology and Chronic Health Evaluation III predictions of hospital mortality in an independent database
33. The pathophysiologic roles of interleukin-6 in human disease
34. Interleukin-I and interleukin-I antagonism
35. Inter-leukin-6 administration has no acute hemodynamic or hematologic effects in the dog
36. Long-term consequences of interleukin-6 over expression in transgenic mice
37. High IL-6 serum levels are associated with septic shock and morality in septic patients with severe leukopenia due to hematological malignancies
38. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value and interplay with other cytokines
39. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome
40. Sepsis and serum cytokine concentrations
41. Cytokine serum level during severe sepsis ia human IL-6 as a marker of severity
42. Multiple forms of IFN-beta/IL-6 in serum and body fluids during acute bacterial infection
43. Persistent elevotion of inflammatory cytokines predicts a poor outcome in ARDS: Plasma IL I beta and IL-6 levels are consistent and efficient predictors of outcome over time
44. Cytokine profile and correlation to the APACHE III and MPM II scores in patient, with sepsis
45. Patterns of cytokine expression in community-acquired pneumonia
46. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia
47. Periplasm, periplasmic spaces, and their relation to bacterial wall structure: Novel secretion of selected periplasmic protein, from Pseudomonas aeruginosa